-
Amaran Biotech Wins Asia-Pacific Biologics CDMO Excellence Award for "Best Fill-Finish"
11 Sep 2025 03:16 GMT
… and advancing their clinical trial Investigational New Drug (IND) applications. … help more drugs accelerate into clinical trials and become … pharmaceutical and biotech industries and successfully led the register and commercialize the antibiotic drug DIFICID …
-
Teva introduces generic Dificid
21 Jul 2025 15:49 GMT
… the generic of Dificid.
Fidaxomicin tablets are an antibiotic medicine used to treat … diarrhea in adults.
[Read more: FDA gives tentative OK for Lupin …
-
Heightened Awareness, Effective Treatment Options Critical to C difficile Management
17 Jun 2025 15:36 GMT
… care center for treatment due to an infection receive antibiotics. Unfortunately, many … use of the specific medicine. Historically, the treatment of mild-to-moderate … as vancomycin (Firvanq; Azurity Pharmaceuticals) or fidaxomicin (Dificid; Merck & Co), …
-
Amaran Biotech Wins "Best CDMO in Automated Aseptic Filling"
27 Mar 2025 03:13 GMT
… Medicine … vaccine manufacturing, and biologics companies. Amaran Biotech … FDA, EMA, ICH, PIC/S, and ISPE. Moving forward, Amaran Biotech … pharmaceutical and biotech industries and successfully led the register and commercialize the antibiotic drug DIFICID …
-
潤雅生技(Amaran Biotech)、日本精化株式会社 (Nippon Fine Chemical) と覚書を締結
10 Mar 2025 03:07 GMT
… CDMO) サービスを専門とするアマランバイオテクノロジー (Amaran Biotechnology Inc.) は本日、日本精化株式会社およびその台湾子会社であるジリオン・ファイン・ケミカルズ・インターナショナル (Zillion … 棟は台湾内政部からグリーンビルディング認証を受けた。 アマランバイオテックの会長兼ジェネラルマネージャであるテシー・チェ博士は、グローバルな製薬・バイオテクノロジー業界で豊富な経験を持ち、抗生物質製剤DIFICID® (フィダキソマイシン) の米国、カナダ、ヨーロッパでの登録・商品化に成功した。 詳しくは、 …
-
Amaran Biotech Signs MOU with Nippon Fine Chemical
07 Mar 2025 03:50 GMT
… experience in pharmaceutical production have … Biotech is a CDMO (Contract Development & Manufacturing Organization) specializing in drug … pharmaceutical and biotech industries and successfully led the register and commercialize the antibiotic drug DIFICID …
-
Amaran Biotech Makes Its Debut at BioJapan 2024 in Yokohama
25 Sep 2024 09:33 GMT
… Organization) offering comprehensive pharmaceutical development and manufacturing … vaccines, gene therapy drugs, new complex drugs, … trials, which have been accepted by the U.S. FDA. Amaran Biotech … and commercialize the antibiotic drug DIFICID® (Fidaxomicin) …
-
Dificid and cost
15 Dec 2023 19:51 GMT
… , the Food and Drug Administration (FDA) has approved Dificid for C. diff-associated … of the active drug in a brand-name medication.
Generics tend to … and your doctor will discuss Dificid in regard to your treatment. The insurance …
-
The Rising Prevalence of Clostridium Difficile Infections Will Drive Clostridium Difficile Infections Treatment Market to US$ 1,727.10 Million by 2031, Says Growth Plus Reports
03 Apr 2023 12:00 GMT
… treatment market. Furthermore, increased medication research activities, new classes of non-antibiotic drugs and vaccines … FDA approval in January 2020 for the DIFICID … trial for RBX2660, an investigational treatment … (European Pharmaceutical Marketing Research …
-
Teva's Innovative Portfolio Fuels 10th Consecutive Quarter of Growth in Q2 2025; Increases 2025 Revenue Outlook for Key Innovative Products and EPS, and Reaffirms All Other Components
30 Jul 2025 11:00 GMT
… tablets (the generic version of Dificid®) in the U.S. … FDA approved AUSTEDO XR as a one pill, once-daily treatment option … generic and innovative medicines and OTC pharmaceutical products from Teva and … States in the generic drug antitrust litigation in the …